Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
Karen Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, U...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-10-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Online Access: | http://www.dovepress.com/clinical-utility-of-fixed-combinations-of-sitagliptinndashmetformin-in-a5548 |
| _version_ | 1797935682946072576 |
|---|---|
| author | Karen Barnard Mary Elizabeth Cox Jennifer B Green |
| author_facet | Karen Barnard Mary Elizabeth Cox Jennifer B Green |
| author_sort | Karen Barnard |
| collection | DOAJ |
| description | Karen Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, USAAbstract: Adequate glycemic control in type 2 diabetes remains a difficult but achievable goal. The development of new classes of glucose-lowering medications, including in particular the incretin-based therapies, provides an opportunity to utilize combinations of medications which target multiple physiologic abnormalities in type 2 diabetes. Complementary combination therapy with sitagliptin–metformin lowers glucose via enhancement of insulin secretion, suppression of glucagon secretion, and insulin sensitization. Use of this combination in diabetes management will provide a greater degree of glycosylated hemoglobin-lowering than that seen with the use of either drug as monotherapy, is unlikely to cause significant hypoglycemia, and is generally associated with weight loss. The effectiveness, tolerability, and potential cost savings associated with the use of sitagliptin–metformin combination therapy make this an attractive option in diabetes management. The possible beneficial effects of this therapy on beta cell function, as well as its cardiovascular impact, remain inadequately explored but are of significant interest.Keywords: diabetes mellitus, sitagliptin, dipeptidyl peptidase-4, combination therapy |
| first_indexed | 2024-04-10T18:19:04Z |
| format | Article |
| id | doaj.art-6927147c9be3449c808246b19776356e |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-04-10T18:19:04Z |
| publishDate | 2010-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-6927147c9be3449c808246b19776356e2023-02-02T07:52:28ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072010-10-012010default363372Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetesKaren BarnardMary Elizabeth CoxJennifer B GreenKaren Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, USAAbstract: Adequate glycemic control in type 2 diabetes remains a difficult but achievable goal. The development of new classes of glucose-lowering medications, including in particular the incretin-based therapies, provides an opportunity to utilize combinations of medications which target multiple physiologic abnormalities in type 2 diabetes. Complementary combination therapy with sitagliptin–metformin lowers glucose via enhancement of insulin secretion, suppression of glucagon secretion, and insulin sensitization. Use of this combination in diabetes management will provide a greater degree of glycosylated hemoglobin-lowering than that seen with the use of either drug as monotherapy, is unlikely to cause significant hypoglycemia, and is generally associated with weight loss. The effectiveness, tolerability, and potential cost savings associated with the use of sitagliptin–metformin combination therapy make this an attractive option in diabetes management. The possible beneficial effects of this therapy on beta cell function, as well as its cardiovascular impact, remain inadequately explored but are of significant interest.Keywords: diabetes mellitus, sitagliptin, dipeptidyl peptidase-4, combination therapyhttp://www.dovepress.com/clinical-utility-of-fixed-combinations-of-sitagliptinndashmetformin-in-a5548 |
| spellingShingle | Karen Barnard Mary Elizabeth Cox Jennifer B Green Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes Diabetes, Metabolic Syndrome and Obesity |
| title | Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes |
| title_full | Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes |
| title_fullStr | Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes |
| title_full_unstemmed | Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes |
| title_short | Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes |
| title_sort | clinical utility of fixed combinations of sitagliptin amp ndash metformin in treatment of type 2 diabetes |
| url | http://www.dovepress.com/clinical-utility-of-fixed-combinations-of-sitagliptinndashmetformin-in-a5548 |
| work_keys_str_mv | AT karenbarnard clinicalutilityoffixedcombinationsofsitagliptinampndashmetforminintreatmentoftype2diabetes AT maryelizabethcox clinicalutilityoffixedcombinationsofsitagliptinampndashmetforminintreatmentoftype2diabetes AT jenniferbgreen clinicalutilityoffixedcombinationsofsitagliptinampndashmetforminintreatmentoftype2diabetes |